Loading clinical trials...

A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1/PHASE2

A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder

A Pilot Trial of One Day Accelerated Intermittent Theta-burst Stimulation Plus D-cycloserine in Suicidal Patients With Borderline Personality Disorder (ONE-D BPD)

NCT07460947•Mclean Hospital

View on ClinicalTrials.gov

Summary

This study tests a new treatment for people with borderline personality disorder (BPD). The treatment combines a medication called D-cycloserine with one day of transcranial magnetic stimulation (TMS). The main questions it aims to answer are: * How many participants complete the treatment? * How do participants feel about the treatment? * Does the treatment have neurophysiological changes on participants? * Does the treatment improve BPD symptoms? * Do the benefits last over time? Participants will be asked to: * Come to the clinic for interviews and testing * Complete weekly questionnaires for 4 weeks before the treatment day * Take D-cycloserine the night before treatment * Attend one treatment day at the clinic. On that day, they may receive up to 20 short TMS sessions (each lasting 3 minutes and separated by 30 minutes). This visit may last up to 12 hours. * Complete weekly questionnaires for 6 weeks after the treatment day.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult (18+) of any gender
•Meets DSM-5 criteria for BPD, per assessment with the Structured Clinic Interview for DSM-5 Personality Disorders (SCID-5-PD), BPD Module
•Moderate to severe SI during the two weeks prior to screening, as indexed by a score of 9 or higher on the Modified Scale for Suicide Ideation - Self Report (Clum \& Yang, 1995)

Exclusion Criteria

•Current manic or hypomanic symptoms, as assessed by the Diagnostic Assessment Research Tool (DART) screener and diagnostic modules, where relevant.
•Current clinically significant psychotic symptoms not better accounted for by BPD, as assessed by the DART psychotic symptoms screener.
•Current alcohol or substance use disorder, that in the opinion of a study PIs, is of sufficient severity to impede engagement in treatment or is associated with significant risk of medical withdrawal, as assessed by the DART.
•Medical documentation or self-report of current anorexia nervosa, bulimia nervosa, or eating disorder not otherwise specified - atypical anorexia nervosa or atypical bulimia nervosa, that is in the opinion of a study PIs is of sufficient severity to be associated with significant medical risks
•Acute suicide risk, sufficient to require immediate hospitalization;
•history of traumatic brain injury (TBI) or concussion involving loss of consciousness or amnesia for ≥24 hours;
•any significant neurological disorder likely to be associated with increased intracranial pressure or cognitive impairment (e.g., epilepsy; Parkinson's disease);
•diagnosed neurodevelopmental disorder (e.g., autism, downs syndrome; Ehlers-Danlos Syndrome) other than attention-deficit hyperactivity disorder (ADHD) or dyslexia
•current diagnosis of delirium or dementia;
•cognitive disorder secondary to a general medical condition
+6 more criteria

Locations (1)

McLean Hospital

Belmont, Massachusetts, United States

Key Dates

Start Date

March 1, 2026

Primary Completion Date

June 1, 2027

Completion Date

December 1, 2027

Last Updated

March 10, 2026

Enrollment

ESTIMATED participants

Conditions

Borderline Personality Disorder (BPD)

Interventions

TMS

DEVICE

D-Cycloserine (DCS)

DRUG

Contacts

Julia Nolan, BA

CONTACT

617-855-3430 jnolan7@mgb.org

Molly Coyle, BS

CONTACT

617-855-2153 mcoyle3@mgb.org

Internal Family Systems Therapy for Borderline Personality Disorder

NCT07342907

Borderline Personality Disorder (BPD)

View study

RECRUITINGNA

Application and Effectiveness of the STEPPS in Patients with BPD, Extending to Their Families with the FC Program

NCT06195553

Borderline Personality Disorder (BPD)

View study

NOT_YET_RECRUITINGNA

Study of Emotional Dysregulation in Complex Post-Traumatic Stress Disorder

NCT06848127

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder

Inclusion Criteria

Exclusion Criteria

Internal Family Systems Therapy for Borderline Personality Disorder

Application and Effectiveness of the STEPPS in Patients with BPD, Extending to Their Families with the FC Program

Study of Emotional Dysregulation in Complex Post-Traumatic Stress Disorder

Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and BPD